Sarepta Therapeutics Securities Class Action Gets The Boot
A Massachusetts federal judge on Tuesday tossed a proposed putative securities class action accusing Sarepta Therapeutics Inc. of misleading investors over the chances of its muscular dystrophy drug eteplirsen hitting the...To view the full article, register now.
Already a subscriber? Click here to view full article